利用多发性骨髓瘤中的CD200-CD200R免疫检查点轴增强CAR T细胞疗法
研究构建表达CD200的多发性骨髓瘤细胞系,发现CD200可抑制靶向BCMA或TnMUC1的临床阶段CAR T细胞;比较CD200R敲除、显性负性CD200R及CD200R-CD28转换受体,发现CD200R-CD28转换可增强CAR T细胞多功能性、细胞毒性、增殖、代谢及慢性抗原暴露下的表现。
要点
- CD200在多发性骨髓瘤异常浆细胞上过表达,是独立的不良预后因素。
- CD200R-CD28转换受体可增强CAR T细胞多功能性、细胞毒性、增殖和代谢。
- CD200R敲除反而损害CAR T细胞活性,对代谢产生不利影响。
核心结论
- CD200介导的免疫抑制在多发性骨髓瘤CAR T细胞治疗中具有重要作用。
- 利用异常浆细胞上的CD200通过CD200R-CD28转换提供共刺激,是增强此类疗法的一种有前景的方法。
研究设计与样本
- 研究为体外和鼠异种移植模型实验,构建表达CD200的多发性骨髓瘤细胞系以模拟异常浆细胞的CD200水平。
- 比较CRISPR-Cas9介导的CD200R敲除、显性负性CD200R共表达及CD200R-CD28转换受体共表达对CAR T细胞的影响。
- CAR T细胞分别靶向BCMA(4-1BB共刺激)或TnMUC1(CD2共刺激),为临床阶段CAR T细胞。
- 使用浆细胞瘤和播散性骨髓为主疾病的鼠异种移植模型验证。
主要发现
- CD200在多发性骨髓瘤异常浆细胞上过表达,是生存的独立负预后因素。
- 多发性骨髓瘤细胞系不表达CD200,为当前临床前模型的潜在局限。
- 工程化表达CD200的细胞系足以抑制靶向BCMA或TnMUC1的临床阶段CAR T细胞。
- CD200R-CD28转换有效增强CAR T细胞多功能性,改善细胞毒性、增殖能力、代谢及慢性抗原暴露试验中的表现。
- CD200R显性负性提供适度益处,而CD200R敲除对CAR T细胞活性有害,对代谢产生不利影响。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 多发性骨髓瘤细胞系不表达CD200,为当前临床前模型的潜在局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with multiple myeloma (MM) treated with B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T cells usually relapse with BCMA+ disease, indicative of CAR T-cell suppression. CD200 is an immune checkpoint that is overexpressed on aberrant plasma cells (aPCs) in MM and is an independent negative prognostic factor for survival. However, CD200 is not present on MM cell lines, a potential limitation of current preclinical models. We engineered MM cell lines to express CD200 at levels equivalent to those found on aPCs in MM and show that these are sufficient to suppress clinical-stage CAR T-cells targeting BCMA or the Tn glycoform of mucin 1 (TnMUC1), costimulated by 4-1BB and CD2, respectively. To prevent CD200-mediated suppression of CAR T cells, we compared CRISPR-Cas9-mediated knockout of the CD200 receptor (CD200RKO), to coexpression of versions of the CD200 receptor that were nonsignaling, that is, dominant negative (CD200RDN), or that leveraged the CD200 signal to provide CD28 costimulation (CD200R-CD28 switch). We found that the CD200R-CD28 switch potently enhanced the polyfunctionality of CAR T cells, and improved cytotoxicity, proliferative capacity, CAR T-cell metabolism, and performance in a chronic antigen exposure assay. CD200RDN provided modest benefits, but surprisingly, the CD200RKO was detrimental to CAR T-cell activity, adversely affecting CAR T-cell metabolism. These patterns held up in murine xenograft models of plasmacytoma, and disseminated bone marrow predominant disease. Our findings underscore the importance of CD200-mediated immune suppression in CAR T-cell therapy of MM, and highlight a promising approach to enhance such therapies by leveraging CD200 expression on aPCs to provide costimulation via a CD200R-CD28 switch.
引用
- Tang Y, Liu W, Kadu S, et al. Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy. Blood. 2024. PMID: 37616575. doi:10.1182/blood.2022018658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。